Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF) . Pilot study
Pannuti, F.; Rossi, A.P.; Di Marco, A.R.; Fruet, F.; Lelli, G.; Strocchi, E.; Rocchetta, G.; Piana, E.; Martoni, A.
Panminerva Medica 23(1): 25-28
1981
ISSN/ISBN: 0031-0808 PMID: 7290722 Document Number: 176341
Twenty postmenopausal patients with metastatic breast cancer no longer responsive to sequential hormone-chemotherapy (medroxyprogesterone acetate [MAP] at high doses and cyclophosphamide + methotrexate + 5-fluorouracil [CMF]) were treated with adriamycin (Adria) alone (80 mg/m2 i.v. every 21 days). Eight patients (40%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 5 mo. (range 1-8), and of survival 17 mo. (range 2-23+) for responders and 10 mo. (range 3-22) for nonresponders (significant statistical difference, P < 0.05). Adria is effective on patients with grossly metastatic disease relapsing after prior sequential hormone-chemotherapy. Remission rates are very close to those achievable both with Adria and with many polychemotherapy regimens in previously untreated patients.